Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
NCT ID: NCT00787657
Last Updated: 2015-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1723 participants
OBSERVATIONAL
2008-06-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* The Study particularly looks at the role of the support of the patient given by the multiple sclerosis nurses.The nurse will provide additional standardised information at start of treatment and will regularly phone the patient to ask standardised questions about the general condition with regard to the treatment, the disease and social support. At the end of the Study it will be assessed if the supportive measures and the standards in terms of adherence management in the hospital have some influence to increase long-term treatment adherence.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program
NCT01233245
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
NCT03408093
Physical Disability in Patients Treated With Betaferon
NCT00873340
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
NCT00461396
Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period
NCT01076595
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Interferon beta-1b (Betaseron, BAY86-5046)
Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon beta-1b (Betaseron, BAY86-5046)
Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many Locations, , Argentina
Many Locations, , Bahrain
Many Locations, , Belgium
Many Locations, , Bosnia and Herzegovina
Many Locations, , Canada
Many Locations, , China
Many Locations, , Colombia
Many Locations, , Czechia
Many Locations, , Egypt
Many Locations, , Estonia
Many Locations, , France
Many Locations, , Germany
Many Locations, , Iran
Many Locations, , Israel
Many Locations, , Italy
Many Locations, , Jordan
Many Locations, , Kuwait
Many Locations, , Lebanon
Many Locations, , Libya
Many Locations, , Mexico
Many Locations, , Netherlands
Many Locations, , New Zealand
Many Locations, , Norway
Many Locations, , Pakistan
Many Locations, , Portugal
Many Locations, , Saudi Arabia
Many Locations, , Singapore
Many Locations, , Slovakia
Many Locations, , Slovenia
Many Locations, , South Korea
Many Locations, , Sweden
Many Locations, , Syria
Many Locations, , Taiwan
Many Locations, , United Arab Emirates
Many Locations, , United Kingdom
Many Locations, , Venezuela
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Patti F, Penaherrera JN, Zieger L, Wicklein EM. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study. BMC Neurol. 2021 Aug 23;21(1):324. doi: 10.1186/s12883-021-02347-w.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
311941
Identifier Type: OTHER
Identifier Source: secondary_id
BF0703
Identifier Type: OTHER
Identifier Source: secondary_id
13852
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.